Clinical Trial Detail

NCT ID NCT03609593
Title Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Nicole Lamanna
Indications

chronic lymphocytic leukemia

Therapies

Rituximab

Bendamustine + Rituximab

Venetoclax

Age Groups: senior adult

No variant requirements are available.